MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2022-002796

Медицинская библиотека · RMD open · 2022

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.

Terslev L, Ostergaard Mikkel, Georgiadis Stylianos, Brahe Cecilie Heegaard, Ellegaard Karen, Dohn U M, Fana Viktoria, Møller Torsten, Juul Lars, Huynh Tuan Khai, Krabbe Simon, Ornbjerg L M, Glinatsi Daniel, Røgind Henrik, Hansen Annette, Nørregaard Jesper, Jacobsen Søren, Jensen Dorte V, Manilo Natalia, Asmussen Karsten, Boesen Mikael, Rastiemadabadi Zoreh, Morsel-Carlsen Lone, Møller Jakob Møllenbach, Krogh Niels Steen, Hetland Merete Lund

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs).

METHODS

Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year. bDMARDs were tapered according to a mandatory clinical guideline to two-thirds of standard dose at baseline, half of dose at week 16 and discontinuation at week 32. Prospective assessments for 2 years included clinical evaluation, conventional radiography, ultrasound and MRI for signs of inflammation and bone changes. Flare was defined as DAS28-CRP ≥2.6 with ∆DAS28-CRP ≥1.2 from baseline. Baseline predictors of flare were assessed by logistic regression analyses.

RESULTS

Of 142 included patients, 121 (85%) flared during follow-up of which 86% regained remission within 24 weeks after flare. Patients that flared were more often rheumatoid factor positive, had tried more bDMARDs and had higher baseline ultrasound synovitis sum scores than those not flaring. For patients on standard dose, predictors of flare within 16 weeks after reduction to two-thirds of standard dose were baseline MRI-osteitis (OR 1.16; 95% CI 1.03 to 1.33; p=0.014), gender (female) (OR 6.71; 95% CI 1.68 to 46.12; p=0.005) and disease duration (OR 1.06; 95% CI 1.01 to 1.11; p=0.020). Baseline predictors for flare within 2 years were ultrasound grey scale synovitis sum score (OR 1.19; 95% CI 1.02 to 1.44; p=0.020) and number of previous bDMARDs (OR 4.07; 95% CI 1.35 to 24.72; p=0.007).

CONCLUSION

The majority of real-world patients with RA tapering bDMARDs flared during tapering, with the majority regaining remission after stepwise dose increase. Demographic and imaging parameters (MR-osteitis/ultrasound greyscale synovitis) were independent predictors of immediate flare and flare overall and may be of importance for clinical decision-making in patients eligible for tapering.

Для цитирования: Terslev L, Ostergaard Mikkel, Georgiadis Stylianos, Brahe Cecilie Heegaard, Ellegaard Karen, Dohn U M, Fana Viktoria, Møller Torsten, Juul Lars, Huynh Tuan Khai, Krabbe Simon, Ornbjerg L M, Glinatsi Daniel, Røgind Henrik, Hansen Annette, Nørregaard Jesper, Jacobsen Søren, Jensen Dorte V, Manilo Natalia, Asmussen Karsten, Boesen Mikael, Rastiemadabadi Zoreh, Morsel-Carlsen Lone, Møller Jakob Møllenbach, Krogh Niels Steen, Hetland Merete Lund. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.. RMD open. 2022. DOI: 10.1136/rmdopen-2022-002796.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.